Jiangsu Hengrui Pharmaceuticals debuted in Hong Kong with shares surging 31% to HK$57.65, raising HK$9.74 billion (US$1.25 billion) in its IPO, one of Hong Kong's largest this year, while its Shanghai-listed shares dipped slightly; this IPO, along with Mirxes' strong debut and a 0.6% rise in the Hang Seng Index, underscores a resurgence in Hong Kong IPO activity driven by Chinese firms seeking secondary listings, with Q1 funds raised nearly quadrupling year-over-year to HK$18.7 billion.
The Hong Kong IPO market is exhibiting a significant resurgence, underscored by the successful debut of Chinese drugmaker Jiangsu Hengrui Pharmaceuticals, whose shares surged 31% to HK$57.65, raising HK$9.74 billion (US$1.25 billion) after being priced at the upper limit of its guidance range. This makes it one of Hong Kong's largest IPOs this year and, coupled with the strong 28% debut rise of Singaporean pharmaceutical firm Mirxes which raised HK$880.5 million, signals robust investor appetite, particularly within the healthcare sector. The positive momentum is further reflected by a 0.6% rise in the benchmark Hang Seng Index on the same day. This revitalization of Hong Kong's capital markets is largely propelled by Chinese A-share companies seeking secondary listings, as noted by the Hong Kong Stock Exchange. Supporting this trend, data from HKEX indicates that funds raised from 17 new listings in the first quarter nearly quadrupled year-over-year to HK$18.7 billion. The slight 0.1% dip in Hengrui's Shanghai-listed shares offers a minor point of contrast but does not significantly detract from the overwhelmingly positive sentiment surrounding its Hong Kong listing and the broader market recovery.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
